Cartesian Therapeutics, Inc.
NASDAQ:RNACBiotechnology
-$0.41 today
- Market cap
- $192.17M
- Beta
- 0.78
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$5.65
Volume 0.17M
Average 0.26M
RNAC Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Cartesian Therapeutics, Inc.NASDAQ: RNAC
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of $39.18M (cash outflow) rose 121.2% year over year, behind the +296.2% change in trailing-twelve-month net income. Sequentially, it fell 57.7% from the prior quarter.
Context
- Net income amounted to 4658.6% of revenue in FY2025, up 4459.7 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of -$53.84M (-58.7%) for the fiscal year ending Dec 2026, a slowdown from the +68.3% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$39.18M-57.7% QoQ
- Last fiscal yearDec 2025
- -$130.3M+68.3% YoY
- LTMMar 2026
- -$151.77M+296.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +121.2% | -267.5% | -388.7 pp |
| 1 year | +68.3% | -58.7% | -127.0 pp |
| 3-year CAGR | — | -10.6% | — |
| 5-year CAGR | -21.1% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (130.3M) USD
- Year-over-year change
- -68.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (130.3M) | -68.3% |
| FY2024 | 2024-12-31 | (77.42M) | +64.8% |
| FY2023 | 2023-12-31 | (219.71M) | -721.0% |
| FY2022 | 2022-12-31 | 35.38M | +237.7% |
| FY2021 | 2021-12-31 | (25.69M) | — |
Net Income vs competitors
How RNAC compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +296.2% is the highest of 9, against a peer median of +3.1%.
- Net income amounts to 8550.6% of revenue for RNAC, versus a peer median of 180.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | €340.16M EUR | +84.7% | +84.4% | 7587.8% | |
| LTM Mar 2026 | $151.77M USD | +296.2% | — | 8550.6% | |
| LTM Mar 2026 | $84.74M USD | -216.1% | +23.4% | 143627.1% | |
| LTM Mar 2026 | $69.87M USD | +152.1% | +61.9% | — | |
| LTM Mar 2026 | $57.09M USD | -16.9% | +0.6% | — | |
| LTM Mar 2026 | $54.64M USD | -17.6% | +16.2% | 167.0% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $42.72M USD | +84.6% | +27.3% | — |
| LTM Mar 2026 | $32.96M USD | — | — | — | |
| LTM Mar 2026 | $26.1M USD | +23.0% | +6.8% | 180.3% | |
| LTM Mar 2026 | $8.38M USD | -42.0% | -24.3% | 16.4% | |
| Peer median (excluding RNAC) | — | +3.1% | +19.8% | 180.3% | |
Competitors are the stored peer set for RNAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (25.69M) | 35.38M | (219.71M) | (77.42M) | (130.3M) |
| Depreciation & Amortization | 1.25M | 1.29M | 843K | 1.15M | 2.96M |
| Deferred Income Tax | 2.4M | (21.4M) | (19M) | 287K | (9.19M) |
| Stock-Based Compensation | 7.72M | 11.19M | 22.52M | 6.58M | 10.52M |
| Change in Working Capital | (48.19M) | (60.38M) | 4.97M | (5.79M) | (8.06M) |
| Accounts Receivables | (2.69M) | 3.32M | 907K | 7.98M | (243K) |
| Inventory | 211K | 920K | 0 | 0 | 0 |
| Accounts Payables | (219K) | 92K | 2.83M | (2.93M) | 1.07M |
| Other Working Capital | (45.5M) | (64.71M) | 1.23M | (10.84M) | (8.89M) |
| Other Non-Cash Items | 2.13M | 2.29M | 159.21M | 51.52M | 60.14M |
| Operating Cash Flow | (60.38M) | (31.63M) | (51.16M) | (23.67M) | (73.94M) |
| Capital Expenditures | (1.09M) | (1.2M) | (206K) | (9.09M) | (5.45M) |
| Acquisitions (Net) | 0 | 0 | 6.56M | 351K | 0 |
| Purchases of Investments | (32.46M) | (33.5M) | 0 | 0 | 0 |
| Sales of Investments | 16.4M | 19.7M | 28.25M | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (17.14M) | (15M) | 34.61M | (8.74M) | (5.45M) |
| Debt Repayment | 0 | 0 | (27.46M) | 0 | 0 |
| Common Stock Issued | 51.96M | 38.98M | 0 | 124.44M | (301K) |
| Common Stock Repurchased | 0 | 0 | (6.17M) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 939K | 235K | 231K | 3.99M | (7.75M) |
| Financing Cash Flow | 52.9M | 39.22M | (13.15M) | 168.43M | (8.06M) |
| Effect of Forex Changes | (3K) | 20K | (53K) | (21K) | 45K |
| Net Change in Cash | (24.63M) | (7.4M) | (29.75M) | 135.99M | (87.41M) |
| Free Cash Flow | (61.47M) | (32.83M) | (51.37M) | (32.77M) | (79.4M) |
Cartesian Therapeutics, Inc.
NASDAQ:RNAC
Intrinsic Alpha fair value
Locked
Current Price
$6.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.